NCT04080531: Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders |
|
|
| Completed | 4 | 165 | US | Pneumococcal 13-valent Conjugate Vaccine, PCV13, Prevnar 13, Trivalent Influenza Vaccine, Flu shot, Flu vaccination, Fluzone, Fluzone HD, Fluzone High-dose, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV | Emory University, Sanofi, National Institutes of Health (NIH), National Cancer Institute (NCI) | Plasma Cell Neoplasm | 05/21 | 12/22 | | |
DANFLU-2, NCT05517174: A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults |
|
|
| Recruiting | 4 | 286900 | Europe | High-Dose Quadrivalent Influenza Vaccine, QIV-HD, Standard-Dose Quadrivalent Influenza Vaccine, QIV-SD | Tor Biering-Sørensen, Sanofi, Statens Serum Institut | Influenza | 05/25 | 08/25 | | |
